Jaguar Health, Inc.

Jaguar Health, Inc.

Jaguar Health is a commercial-stage biopharmaceutical company founded to develop and commercialize novel prescription drugs derived from the Amazonian plant Croton lechleri per public record. Its only approved drug currently marketed is Mytesi (crofelemer), indicated to treat diarrhea in HIV/AIDS patients on antiretroviral therapy (per FDA, 2012). The firm also has a pipeline focused on rare diseases, including short bowel syndrome and congenital diarrheal disorders. The company's core asset is crofelemer, a plant-based anti-secretory agent that has been studied for a range of GI conditions. Jaguar Health funds its operations through public equity offerings, at-the-market offerings, and debt financing, as disclosed in SEC filings. No specific AUM or deployment numbers are disclosed because the firm is a listed company, not an investment entity. Jaguar Health is a single operating company with no family-office or asset-management structure. The company has reported minimal revenue from Mytesi sales and has a history of operating losses per SEC filings. No philanthropic foundations, partner offices, or investment vehicles are publicly associated. The firm's structural differentiator is its focus on plant-based, FDA-approved prescription drugs for GI diseases, with a rare disease pipeline that leverages the same mechanism of action. That model places it in a narrow niche between natural-product pharma and conventional drug development.